Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones

Journal of Chemotherapy

Volumn 18, Issue 4, 2006, Pages 366-372

  Blondeau, J M ^a,b   Blondeau, L D ^a   Hesje, C ^a   Borsos, S ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Gatifloxacin; Gemifloxacin; Killing activity; Levofloxacin; Moxifloxacin; Streptococcus pneumoniae

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TETRACYCLINE;

ARTICLE; BACTERIUM COLONY; CELL VIABILITY; CLINICAL FEATURE; DOSE RESPONSE; DRUG EXPOSURE; GENE MUTATION; INOCULATION; MICROBIAL GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 33749000564     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.4.366     Document Type: Article

References (24)

1. Davidson RJ, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346(10):747-750.
2. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005; 41:118-121.
3. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1756-1758.
4. Blondeau JM, Hansen G, Metzler KL, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16(Suppl. 3):1-19.
5. Blondeau J, Zhao X, Hansen GT, Drlica K. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433-438.
6. Hansen G, Metzler KL, Drlica K, Blondeau JM. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47(1):440-441.
7. Metzler KL, Hansen G, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and resistant Staphylococcus aureus. Int. J Antimicrob Agents 2004; 24:161-167.
8. Hansen G, Zhao X, Drlica K, Blondeau JM. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27: 120-124.
9. Hansen G, Blondeau JM. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric gram-negative urinary tract infection pathogens. J Chemother 2005; 17(5):484-492.
10. Frisch AW, Tripp JT, Barrett Jr. CD, Pidgeon BE. Specific polysaccaride content of pneumoni lungs. J Exp Med 1942; 76:505-510.
11. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis 2004; 38(Suppl. 4):S357-362.
12. Lim S, Bast D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerging Infect Dis 2003; 9(7):833-837.
13. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47:129-140.
14. Blondeau JM, Hansen G, Metzler KL, Borsos S, Chau J. Optimal killing of Streptococcus pneumoniae by gemifloxacin, levofloxacin and moxifloxacin. In: Gillespie SH, Tillotson GS, eds. Novel Perspectives in Antibacterial Action. London: Royal Society of Medicine Press Limited; 2002:15-26.
15. Klugman KP, Capper T. Concentration-dependent killing of antibiotic resistant pneumococci by the methoxyquinolone moxifloxacin. J Antimicrob Chemother 1997; 40:797-802.
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard (M7-A7), 2006.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement (M100-S15), 2005, vol 24.
18. Doem GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41: 139-148.
19. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47(6): 1867-1874.
20. Felmingham D, Farrell DJ, Reinert R, Rene, Morrissey I. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000). J Infect 2004; 48: 39-55.
21. Blondeau JM. A review of the comparative in vitro activity of 12 antimicrobial agents with a focus on 4 new "respiratory quinolones". J Antimicrob Chemother 1999; 43(Suppl.B):1-11.
22. Chen DK, McGeer A, De Azavedo J, Low DE, The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341:233-239.
23. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiple resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43(5):1310-1313.
24. Blondeau JM, Tillotson GS. Antibiotic dosing: do we dose to cure the individual or do we treat the greater societal needs? Therapy 2005; 2(4):511-516.